Envoy Medical (NASDAQ: COCH) has announced positive 12-month data from the first ten participants in Stage 1 of its pivotal clinical trial evaluating the investigational fully implanted Acclaim cochlear implant.
According to Envoy, the first-of-its-kind study showed that mean consonant-nucleus-consonant (CNC) word recognition scores for the Stage 1 cohort improved to 53.2% at 12 months from 15.2% pre-implantation, a 38.0 percentage point gain that continued to build on the 24.0 percentage point improvement reported at 6 months.
In a statement, Brent Lucas, CEO of Envoy, commented, “We hope that our shareholders and investors are as encouraged as we are by the updated data readout from the first ten participants in Stage 1 of the Acclaim clinical study. While we believed the six-month data readout from Stage 1 was promising, we reasonably expected to see meaningful continued improvement through 12 months and are seeing objective evidence supporting that belief. While the study remains ongoing and these interim results are preliminary, these data reinforce our conviction that the future of cochlear implants is in fully implanted devices using Invisible Hearing technology.”
